Lymph node involvement beyond peripancreatic region in pancreatic head cancers: When results belie expectations

Pancreas

Volumn 42, Issue 2, 2013, Pages 239-248

  Golse, Nicolas ^a   Lebeau, Roger ^a   Lombard Bohas, Catherine ^a   Hervieu, Valerie ^a   Ponchon, Thierry ^a   Adham, Mustapha ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

exocrine adenocarcinoma; lymphadenectomy; pancreas; pancreatic neoplasm; prognostic factors; superior mesenteric artery

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FROZEN SECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; LENGTH OF STAY; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PANCREATITIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SUPERIOR MESENTERIC ARTERY; SURVIVAL RATE; TUMOR DIFFERENTIATION; VASCULAR SURGERY;

AGED; CARCINOMA, PANCREATIC DUCTAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MESENTERIC ARTERY, SUPERIOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 84874107104     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31825f80a9     Document Type: Article

References (66)

1. Moutardier V, Giovannini M, Magnin V, et al. How to improve treatment of resectable pancreatic adenocarcinomas? Surgical resection, histopathological examination, adjuvant therapies [in French]. Gastroenterol Clin Biol. 2004;28(11):1083-1091.
2. Morin B, Chiche L, Salame E, et al. Results of resection for ductal adenocarcinoma of the pancreatic head [in French]. Ann Chir. 2006;131(9):518-523.
3. Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75(8):2069-2076.
4. Yokoyama Y, Nimura Y, Nagino M. Advances in the treatment of pancreatic cancer: Limitations of surgery and evaluation of new therapeutic strategies. Surg Today. 2009;39(6):466-475.
5. Steele GD, Osteen RT, Winchester DP, et al. Clinical highlights from the National Cancer Database: 1994. CA Cancer J Clin. 1994;44(2):71-80.
6. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225(5):621-633; discussion 633-636.
7. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 Consecutive resections without an operative mortality. Ann Surg. 1990;211(4):447-458.
8. Nitecki SS, Sarr MG, Colby TV, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg. 1995;221(1):59-66.
9. Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg. 1987;206(3):358-365.
10. Ishikawa O, Ohigashi H, Sasaki Y, et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery. 1997;121(3):244-249.
11. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. 2011;34(3):321-325.
12. Lowery MA, O'Reilly EM. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs. 2011;25(4):207-216.
13. Garcea G, Dennison AR, Pattenden CJ, et al. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. J Pancreas. 2008;9(2):99-132.
14. Zacharias T, Jaeck D, Oussoultzoglou E, et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg. 2007;11(3):350-356.
15. Michalski CW, Kleeff J, Wente MN, et al. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg. 2007;94(3):265-273.
16. Partensky C. Pancreatic surgery in France. Surg Today. 2010;40(10):895-901.
17. Baulieux J, Delpero Jr. Surgical treatment of pancreatic cancer: Curative resections [in French]. Ann Chir. 2000;125(7):609-617.
18. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;28(3):219-230.
19. Isaji S, Kawarada Y, Uemoto S. Classification of pancreatic cancer: Comparison of Japanese and UICC classifications. Pancreas. 2004;28(3):231-234.
20. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-196.
21. Butturini G, Daskalaki D, Molinari E, et al. Pancreatic fistula: definition and current problems. J Hepatobiliary Pancreat Surg. 2008;15(3):247-251.
22. Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): An International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1): 20-25.
23. Edge SB, Byrd DR. AJCC Cancer Staging Manual. France: Springer Verlag. 2010:648.
24. Adham M, Singhirunnusorn J. Surgical technique and results of total mesopancreas excision (TMpE) in pancreatic tumors. Eur J Surg Oncol. 2012;38(4):340-345.
25. Imanaga H. A new method of pancreaticoduodenectomy designed to preserve liver and pancreatic function. Surgery. 1960;47: 577-586.
26. Sauvanet A. Lymph node resection for carcinoma of the pancreas [in French]. J Chir (Paris). 2008;145(spec no. 4):12S31-12S35.
27. Takamori H, Kanemitsu K, Hirota M, et al. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Ann Surg Oncol. 2011;18(4):1110-1115.
28. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: Utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227-1234.
29. Pisters PWT, Evans DB. Cisplatin, fluorouracil, interferon-alpha, and radiation as adjuvant therapy for resected pancreatic cancer: Is there a future for this regimen and/or should we change our approach to research and treatment of patients with pancreatic cancer? Ann Surg. 2008;248(2):152-153.
30. Czito BG, Willett CG. Adjuvant radiation therapy for distal pancreatic cancer: Is there a role? Ann Surg Oncol. 2010;17(12):3082-3084.
31. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA. 2010;304(10):1073-1081.
32. Saif MW. Adjuvant therapy of pancreatic cancer: Beyond gemcitabine. Highlights from the ''2011 ASCO Gastrointestinal Cancers Symposium.'' San Francisco, CA, USA. January 20-22, 2011. In: J Pancreas. 2011;12:106-109.
33. Pawlik TM, Gleisner AL, Cameron JL, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery. 2007;141(5):610-618.
34. Perini MV, Montagnini AL, Jukemura J, et al. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford). 2008;10(5):356-362.
35. Kato K, Yamada S, Sugimoto H, et al. Prognostic factors for survival after extended pancreatectomy for pancreatic head cancer: Influence of resection margin status on survival. Pancreas. 2009;38(6):605-612.
36. Henne-Bruns D, Vogel I, Lu? ttges J, et al. Surgery for ductal adenocarcinoma of the pancreatic head: Staging, complications, and survival after regional versus extended lymphadenectomy. World J Surg. 2000;24(5):595-601; discussion 601-602.
37. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg. 2003;237(1):74-85.
38. van Heek NT, Kuhlmann KFD, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: A systematic review and an evaluation of intervention in the Netherlands. Ann Surg. 2005;242(6):781-788, discussion 788-790.
39. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128-1137.
40. van Roest MHG, Gouw ASH, Peeters PMJG, et al. Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: Perineural growth more important prognostic factor than tumor localization. Ann Surg. 2008;248(1):97-103.
41. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2011;253(5):968-974.
42. Benassai G, Mastrorilli M, Mosella F, et al. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res. 1999;18(1):23-28.
43. Delcore R, Rodriguez FJ, Forster J, et al. Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. Am J Surg. 1996;172(5): 463-468; discussion 468-469.
44. Cohen JR, Kuchta N, Geller N, et al. Pancreaticoduodenectomy. A 40-year experience. Ann Surg. 1982;195(5):608-617.
45. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 Patients. Ann Surg. 1995;221(6):721-731; discussion 731-733.
46. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreasV616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4(6):567-579.
47. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68-72; discussion 72-73.
48. Fortner JG, Klimstra DS, Senie RT, et al. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996;223(2):147-153.
49. Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: A series of 30 patients collected from 3 institutions. Pancreas. 2008;37(4):352-357.
50. Lucey B, Stuhlfaut J, Soto J. Mesenteric lymph nodes: detection and significance on MDCT. Am J Roentgenol. 2005;184(1):41.
51. Ishigami K, Yoshimitsu K, Irie H, et al. Significance of mesenteric lymphadenopathy after pancreaticoduodenectomy for periampullary carcinomas: Evaluation with serial MDCT studies. Eur J Radiol. 2007;61(3):491-498.
52. Kayahara M, Funaki K, Tajima H, et al. Surgical implication of micrometastasis for pancreatic cancer. Pancreas. 2010;39(6): 884-888.
53. Verbeke CS, Leitch D, Menon KV, et al. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232-1237.
54. Pessaux P, Regenet N, Arnaud JP. Resection of the retroportal pancreatic lamina during a cephalic pancreaticoduodenectomy: first dissection of the superior mesenteric artery [in French]. Ann Chir. 2003;128(9):633-636.
55. Jamieson NB, Foulis AK, Oien KA, et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010;251(6):1003-1010.
56. Reinders ME, Allema JH, van Gulik TM, et al. Outcome of microscopically nonradical, subtotal pancreaticoduodenectomy (Whipple's resection) for treatment of pancreatic head tumors. World J Surg. 1995;19(3):410-414; discussion 414-415.
57. Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg. 1996;223(6):718-725; discussion 725-728.
58. Klinkenbijl JH, Jeekel J, Schmitz PI, et al. Carcinoma of the pancreas and periampullary region: Palliation versus cure. Br J Surg. 1993;80(12):1575-1578.
59. Shimada K, Sakamoto Y, Nara S, et al. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg. 2010;34(8): 1908-1915.
60. Sommerville C, Limongelli P, Pai M, et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: An analysis of clinicopathological factors. J Surg Oncol. 2009;100(8):651-656.
61. Massucco P, Ribero D, Sgotto E, et al. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: Not just a matter of numbers. Ann Surg Oncol. 2009;16(12):3323-3332.
62. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618-628; discussion 628-630.
63. Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg. 1997;226(3):248-257; discussion 257-260.
64. Figueras J, Codina-Barreras A, López-Ben S, et al. Cephalic duodenopancreatectomy in periampullary tumours. Dissection of the superior mesenteric artery as aninitial approach. Description of the technique and an assessment of our initial experience [in Spanish]. Cir Esp. 2008;83(4):186-193.
65. Kennedy TJ, Cassera MA, Wolf R, et al. Surgeon volume versus morbidity and cost in patients undergoing pancreaticoduodenectomy in an academic community medical center. J Gastrointest Surg. 2010;14(12):1990-1996.
66. Hardacre JM. Is there a learning curve for pancreaticoduodenectomy after fellowship training? HPB Surg. 2010;2010:230287.